To evaluate the activity of HD-derived anti-BCMA CAR T cells in a clinically relevant model, we designed a whole BM ex vivo cytotoxicity assay using BM samples from patients with multiple myeloma to reflect the immunosuppressive effects of the BM tumor microenvironment (Fig. 4A). This evidence concerns the gene TNFRSF17 and neoplasm.